Oncology portfolio of chemotherapies and targeted therapies described as Brazil's largest chemotherapy offering.
Oncológicos is Libbs Farmacêutica's oncology portfolio of chemotherapy agents and targeted therapies, entered in 2004, presented on a dedicated official page for healthcare professionals. The company describes it as the largest chemotherapy portfolio available in the country, with 18 products in 43 presentations and more than 2.8 million patients treated.
The portfolio includes the Fauld chemotherapy line (cisplatin, carboplatin, doxorubicin, methotrexate, fluorouracil, cytarabine, vinca alkaloids), taxanes Ontax and Docelibbs, and targeted therapies Zayon (enzalutamide), Zostide (abiraterone), Anastrolibbs (anastrozole), Poemmy (fulvestrant), plus biologics Zedora (trastuzumab) and Elovie (bevacizumab). Zedora was approved in 2017 as Brazil's first trastuzumab biosimilar.
Amgen
Amgen Oncology
amgen.com
EMS
EMS — Hospital & Institutional Medicines
ems.com.br
Eurofarma
Eurofarma Oncologia
eurofarma.com.br
Fresenius Kabi
Fresenius Kabi Brasil Biopharma
fresenius-kabi.com
Cristália
Oncology APIs & Oncology Drugs
cristalia.com.br
| Attribute | Oncológicos | Amgen Oncology | EMS — Hospital & Institutional Medicines | Eurofarma Oncologia | Fresenius Kabi Brasil Biopharma | Oncology APIs & Oncology Drugs | |
|---|---|---|---|---|---|---|---|
| Provider | | Amgenamgen.comPublic | | | | | |
| Founded | 1958 | 1980 | 1964 | 1972 | — | 1972 | |
| Sells To | Consumers, Enterprise | — | Consumers, Healthcare Providers, Hospitals | Consumers | — | Consumers, Hospitals | |
| Pricing Model | Recurring, Software | — | B2B, Product Sales | Recurring, Software, Transactional | — | Product Sales | |
| Ownership | Private | — | Family-owned, Private | Public | — | Private |
Provider
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private
Founded 1980
Sells To —
Pricing Model —
Ownership —
Provider
Founded 1964
Sells To Consumers, Healthcare Providers, Hospitals
Pricing Model B2B, Product Sales
Ownership Family-owned, Private
Provider
Founded 1972
Sells To Consumers
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider
Founded —
Sells To —
Pricing Model —
Ownership —
MSD's oncology medicines portfolio marketed in Brazil through its human-health division.
Prescription medicines from EMS for pharmacists, physicians and healthcare professionals across practically all medical specialties.
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
Portfolio of high-complexity biologic and biosimilar medicines produced and distributed by Bionovis across five medical specialties.
MSD's oncology medicines portfolio marketed in Brazil through its human-health division.
Prescription medicines from EMS for pharmacists, physicians and healthcare professionals across practically all medical specialties.
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
Portfolio of high-complexity biologic and biosimilar medicines produced and distributed by Bionovis across five medical specialties.
